Compare Wockhardt with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs PANACEA BIOTECH - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT PANACEA BIOTECH WOCKHARDT/
PANACEA BIOTECH
 
P/E (TTM) x -53.8 9.5 - View Chart
P/BV x 1.2 3.7 32.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT   PANACEA BIOTECH
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
PANACEA BIOTECH
Mar-19
WOCKHARDT/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,012354 286.2%   
Low Rs532138 384.6%   
Sales per share (Unadj.) Rs355.974.6 477.3%  
Earnings per share (Unadj.) Rs-60.36.7 -902.5%  
Cash flow per share (Unadj.) Rs-46.815.5 -301.8%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.857.2 450.7%  
Shares outstanding (eoy) m110.6361.25 180.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.3 65.8%   
Avg P/E ratio x-12.836.8 -34.8%  
P/CF ratio (eoy) x-16.515.9 -104.0%  
Price / Book Value ratio x3.04.3 69.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,37915,061 566.9%   
No. of employees `0006.32.3 270.3%   
Total wages/salary Rs m9,3711,471 637.1%   
Avg. sales/employee Rs Th6,295.01,973.6 319.0%   
Avg. wages/employee Rs Th1,498.3635.6 235.7%   
Avg. net profit/employee Rs Th-1,066.3176.8 -603.1%   
INCOME DATA
Net Sales Rs m39,3694,567 862.0%  
Other income Rs m1,20245 2,683.7%   
Total revenues Rs m40,5714,612 879.7%   
Gross profit Rs m182,030 0.9%  
Depreciation Rs m1,495540 276.9%   
Interest Rs m2,5551,048 243.7%   
Profit before tax Rs m-2,830486 -582.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m25777 333.3%   
Profit after tax Rs m-6,669409 -1,630.0%  
Gross profit margin %044.4 0.1%  
Effective tax rate %-9.115.9 -57.3%   
Net profit margin %-16.99.0 -189.1%  
BALANCE SHEET DATA
Current assets Rs m33,7962,415 1,399.7%   
Current liabilities Rs m26,9179,077 296.5%   
Net working cap to sales %17.5-145.9 -12.0%  
Current ratio x1.30.3 472.0%  
Inventory Days Days7965 121.9%  
Debtors Days Days8971 125.8%  
Net fixed assets Rs m39,6648,333 476.0%   
Share capital Rs m55361 902.4%   
"Free" reserves Rs m27,9683,443 812.4%   
Net worth Rs m28,5223,504 814.0%   
Long term debt Rs m21,731461 4,711.9%   
Total assets Rs m81,62013,755 593.4%  
Interest coverage x-0.11.5 -7.3%   
Debt to equity ratio x0.80.1 578.9%  
Sales to assets ratio x0.50.3 145.3%   
Return on assets %-5.010.6 -47.6%  
Return on equity %-23.411.7 -200.3%  
Return on capital %-7.738.7 -19.8%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m9,8071,203 815.2%   
Fx outflow Rs m1,789467 383.3%   
Net fx Rs m8,019736 1,088.9%   
CASH FLOW
From Operations Rs m6841,049 65.3%  
From Investments Rs m6,302-54 -11,780.2%  
From Financial Activity Rs m-7,695-1,011 760.8%  
Net Cashflow Rs m-664-20 3,370.6%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.6 383.3%  
FIIs % 7.7 1.3 592.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   67,757 10,259 660.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  FDC LTD.  SUN PHARMA  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Aug 7, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS